Survodutide
Explore peptide research and guides on survodutide.
Survodutide
How Survodutide Differs from Other Dual Agonists
Survodutide shares the GLP-1/glucagon mechanism with mazdutide but targets MASH with FDA Breakthrough status. How it compares to tirzepatide and retatrutide.
SurvodutideSurvodutide and MASH: Why This Drug Targets Liver Fat
Survodutide achieved 47-62% MASH resolution in its Phase 2 trial. How the GLP-1/glucagon agonist targets liver fat through glucagon receptor activation.
SurvodutideSurvodutide Clinical Trial Data
Survodutide, a GLP-1/glucagon dual agonist, achieved up to 19% weight loss and 62% MASH resolution in phase 2 trials. Full clinical data breakdown.
SurvodutideSurvodutide: The Dual GLP-1/Glucagon Liver Drug
Survodutide is a dual GLP-1/glucagon receptor agonist targeting liver fat in MASH. Phase 2 results, weight loss data, mechanism, and Phase 3 trial status.